...Boehringer Ingelheim has decided not to enforce patents on its anti-HIV drug, Nevirapine, in 78 low-income African and Asian countries...In a statement on its website, Boehringer says it will issue “short, non-assert declarations”, or licences, to any generic producer that has been pre-qualified by the World Health Organization for supplying Nevirapine to these 78 countries. [also refers to Ranbaxy Laboratories, Cipla, Aurobindo Pharmaceuticals, Hetero Drugs, Strides Arcolab]